(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

EPIZYME

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

EPIZYME

ST13

US500000088979999

Class

5, 42

Filing

88979999

Registration

6268511

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

31

Latest update

02/10/2026

Trademark type

Word

Nice classes

5, 42

Filing date

05/30/2019

Registration date

02/09/2021

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

02/09/2021

Last transaction

02/10/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

01/30/2020

First use in commerce

01/30/2020

Drawing code

4

Owner type

03

Owner location

Cambridge, MA, US

Examiner

AURAND, KYLE C

Law office

N80

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Epizyme, Inc.

Representatives

Douglas R. Wolf WOLF, GREENFIELD & SACKS, P.C.

Technical classification

Nice Classes

Class 5Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

pharmaceutical products for the treatment of human diseases and disorderscancercell proliferative diseases and disordershematological diseases and disordersdiseases and disorders driven by epigenetic mechanisms

Class 42

pharmaceutical research and development in the fields of cancercell proliferative diseases and disordershematological diseases and disordersgenetic diseases and disordersdiseases and disorders driven by epigenetic mechanisms; all of the foregoing for human medicinal purposes

Publications

History of USPTO decisions and trademark events.

31 publications found

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

02/09/2026

R.PR

REGISTERED-PRINCIPAL REGISTER

02/09/2021

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

01/06/2021

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

01/05/2021

SUPC

STATEMENT OF USE PROCESSING COMPLETE

01/04/2021

DPCC

DIVISIONAL PROCESSING COMPLETE

01/04/2021

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

12/29/2020

IUAF

USE AMENDMENT FILED

12/10/2020

DRRR

DIVISIONAL REQUEST RECEIVED

12/10/2020

ERTD

TEAS REQUEST TO DIVIDE RECEIVED

12/10/2020

EISU

TEAS STATEMENT OF USE RECEIVED

12/10/2020

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

06/16/2020

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

04/21/2020

PUBO

PUBLISHED FOR OPPOSITION

04/21/2020

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

04/01/2020

ALIE

ASSIGNED TO LIE

03/19/2020

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/14/2020

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/20/2020

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/20/2020

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

02/20/2020

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

02/20/2020

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

02/20/2020

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

02/20/2020

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

02/20/2020

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/20/2020

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

08/21/2019

GNRT

NON-FINAL ACTION E-MAILED

08/21/2019

CNRT

NON-FINAL ACTION WRITTEN

08/21/2019

DOCK

ASSIGNED TO EXAMINER

08/20/2019

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

06/13/2019

NWAP

NEW APPLICATION ENTERED

06/03/2019

Continuous trademark protection

Get notified about every new filing that threatens EPIZYME or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.